.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,157,121

« Back to Dashboard

Claims for Patent: 9,157,121

Title:Method of treatment based on polymorphisms of the KCNQ1 gene
Abstract: The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
Inventor(s): Wolfgang; Curt D. (Germantown, MD), Polymeropoulos; Mihael H. (Potomac, MD)
Assignee: Vanda Pharmaceuticals, Inc. (Washington, DC)
Application Number:14/632,914
Patent Claims: 1. A method of administering iloperidone or a metabolite thereof to treating a human individual the method comprising: determining or having determined the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 ; and in the case that the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, administering to the individual a first quantity of iloperidone or a metabolite thereof, and in the case that the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1 is not associated with an increased risk of QT prolongation, administering to the individual a second quantity of iloperidone or a metabolite thereof, wherein the first quantity is less than the second quantity, wherein a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1 is associated with an increased risk of QT prolongation, and the KCNQ1 genotype not associated with an increased risk of QT prolongation is non-CC at position 78927 of SEQ. ID. 1.

2. The method of claim 1, wherein the method comprises administering iloperidone to the individual.

3. The method of claim 1, wherein the method comprises administering a metabolite of iloperidone to the individual, wherein the metabolite is 1-[4-[3-[4-(6-Fluoro-1,2-benzisoxazol-3-y1)-1 -piperidinyl] propoxy]-3 -methoxyphenyl]ethanol.

4. The method of claim 1, further comprising: determining or having determined at least a portion of the patient's CYP2D6 genotype, in the case that the individual's CYP2D6G1846A genotype is AA or GA or the individual's CYP2D6C100T genotype is TT or CT, and the individual has a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1, administering to the individual the first quantity of iloperidone or the metabolite thereof, and in the case that the individual's CYP2D6G1846A genotype is GG or the individual's CYP2D6C100T genotype is CC, and the individual's KCNQ1 genotype is non-CC at position 78927 of SEQ. ID. 1, administering to the individual the second quantity of iloperidone or the metabolite thereof.

5. The method of claim 1, wherein the human individual is suffering from at least one condition selected from a group consisting of: schizophrenia, including paranoid schizophrenia, catatonic schizophrenia, disorganized schizophrenia, undifferentiated schizophrenia, and residual schizophrenia; schizoaffective disorder, depression, bipolar mania/depression, cardiac arrythmia, Tourette's Syndrome, a psychotic disorder, including brief psychotic disorder, a psychotic disorder not otherwise specified, a psychotic disorder due to a general medical condition, and a substance-induced psychotic disorder; a delusional disorder, and schizophreniform disorder.

6. The method of claim 1, wherein the second quantity of iloperidone is 24 mg/day.

7. The method of claim 1, wherein the KCNQ 1 genotype not associated with an increased risk of QT prolongation is AC or AA at position 78927 of SEQ ID NO: 1.

8. A method of treating a human individual with iloperidone or a metabolite thereof, the method comprising: characterizing an expression product of the individual's KCNQ1 gene; and in the case that the characterized expression product corresponds to a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1, administering to the individual a first quantity of iloperidone or a metabolite thereof, and in the case that the characterized expression product corresponds to a KCNQ1 genotype of non-CC at position 78927 of SEQ. ID. 1, administering to the individual a second quantity of iloperidone or a metabolite thereof, wherein the first quantity is less than the second quantity.

9. The method of claim 8, further comprising: characterizing an expression product of the individual's CYP2D6 gene; and determining whether the characterized expression product corresponds to a CYP2D6 polymorphism selected from a group consisting of: CYP2D6G1846A and CYP2D6C100T.

10. The method of claim 8, wherein the second quantity of iloperidone is 24 mg/day.

11. The method of claim 8, wherein the non-CC KCNQ1 genotype at position 78927 of SEQ ID NO: 1 is AC or AA.

12. A method of administering iloperidone or a metabolite thereof to a human individual suffering from long QT syndrome (LQTS), the method comprising: determining or having determined the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1; and administering to the individual a quantity of the iloperidone or the metabolite thereof based on the individual's KCNQ1 genotype at position 78927 of SEQ. ID. 1, wherein a first quantity is administered to the individual in a case in which the individual has a KCNQ1 genotype of CC at position 78927 of SEQ. ID. 1, and a second quantity is administered to the individual in a case in which the individual has a KCNQ1 genotype that is non-CC at position 78927 of SEQ. ID. 1.

13. The method of claim 12, further comprising: determining or having determined the individual's CYP2D6 genotype; and determining whether the individual's CYP2D6 genotype corresponds to a CYP2D6 polymorphism selected from a group consisting of: CYP2D6G1846A and CYP2D6C100T.

14. The method of claim 12, wherein the second quantity of iloperidone is 24 mg/day.

15. The method of claim 12, wherein the non-CC KCNQ1 genotype at position 78927 of SEQ ID NO: 1 is AC or AA.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc